Diminished transcriptional activity and splicing changes drive gene length-biased rewiring in the aging transcriptome.
Aging shrinks the brain's RNA-making machinery, biasing expression toward shorter genes and away from those needed for brain health—suggesting novel anti-aging targets.
This PNAS study reveals that aging leads to a global reduction in RNA polymerase II transcriptional activity rather than rate, biasing expression toward shorter genes and away from long neurodevelopmental genes, with increased aberrant splicing in the aged brain. The identification of RNAPII-Mediator complex disruption as a key aging mechanism provides potential transcriptional control targets for anti-aging drug development.
What the study was
- Study design
- Multi-modal molecular study: total RNA-seq (nascent transcription), long-read RNA-seq, ChIP-seq; both mouse and human tissue analysis (Northwestern University / UCSF Gladstone)
- Population
- Aged vs young mouse tissues (liver, brain) and human aging tissue datasets (RNA-seq from multiple human tissues)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Proceedings of the National Academy of Sciences USA
Why it surfaced
PNAS from Shilatifard lab (Northwestern epigenetics powerhouse); multi-modal mechanistic study with both mouse and human tissue data; identifies RNAPII-Mediator disruption as anti-aging drug target. Clinical relevance is indirect/long-term; primarily a basic science find.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.